Document is current
Any future updates will be listed below
-
Authors
Borch, Troels Holz https://orcid.org/0000-0002-4402-9281
Andersen, Rikke
Ellebaek, Eva
Met, Özcan
Donia, Marco
Marie Svane, Inge
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00937625 at ClinicalTrials.govnct02379195 at ClinicalTrials.govDocuments that mention this clinical trial
612 Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis
https://doi.org/10.1136/jitc-2022-sitc2022.0612
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
https://doi.org/10.1136/jitc-2022-006436
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2024-010575
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
nct02354690 at ClinicalTrials.govDocuments that mention this clinical trial
612 Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis
https://doi.org/10.1136/jitc-2022-sitc2022.0612
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
https://doi.org/10.1136/jitc-2022-006436
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2024-010575
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
nct01995344 at ClinicalTrials.govDocuments that mention this clinical trial
612 Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis
https://doi.org/10.1136/jitc-2022-sitc2022.0612
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2021-002703
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
https://doi.org/10.1136/jitc-2022-006436
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2024-010575
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
nct02278887 at ClinicalTrials.govDocuments that mention this clinical trial
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
nct03645928 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
https://doi.org/10.1136/jitc-2020-000848
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
https://doi.org/10.1136/jitc-2023-008372
Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
https://doi.org/10.1136/bmjgast-2022-000989
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2024-010575
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
https://doi.org/10.1136/jitc-2023-006847
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
Documents that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.458
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
https://doi.org/10.1136/jitc-2021-sitc2021.492
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results
https://doi.org/10.1136/jitc-2024-sitc2024.1488
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
https://doi.org/10.1200/jco.2024.42.16_suppl.9505
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007218
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
-
Funding
Funding for this research was provided by:
The Beckett Foundation
Aase og Ejnar Danielsens Fond
The Danish Council for Independent Research
The Danish Cancer Society
Herlev and Gentofte Hospital Research Council
- License Information
